Compare DAKT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | PHAT |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 942.6M |
| IPO Year | 1994 | 2019 |
| Metric | DAKT | PHAT |
|---|---|---|
| Price | $21.58 | $13.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $26.00 | $17.33 |
| AVG Volume (30 Days) | 423.5K | ★ 1.3M |
| Earning Date | 03-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $770,283,000.00 | $147,190,000.00 |
| Revenue This Year | $13.76 | $220.82 |
| Revenue Next Year | $7.35 | $82.87 |
| P/E Ratio | $147.22 | ★ N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $10.24 | $2.21 |
| 52 Week High | $24.38 | $18.31 |
| Indicator | DAKT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 61.89 | 43.41 |
| Support Level | $21.01 | $13.23 |
| Resistance Level | $22.67 | $14.68 |
| Average True Range (ATR) | 0.67 | 1.06 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 66.35 | 18.59 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.